• br Experimental and simulation section br Acknowledgments Fi

  2024-01-25

  

  Experimental and simulation section Acknowledgments Financial support for this work was provided by the National Natural Science Foundation of China (No. 81101688). We would like to thank NC State University High Performance Computing Center for providing us computing resources, and Dr. Lihui

• br The role of apelin in hepatic diseases The

  2024-01-25

  

  The role of apelin in hepatic diseases The involvement of the apelin/APJ system in liver physiology and pathology has been proven in numerous studies (Table 6). For instance, in the experiment of Emam et al. [63] on rats suffering from hepatic injury, apelin decreased the levels of ALT, AST and L

• The objectives of this study

  2024-01-25

  

  The objectives of this study were to investigate 1) the mRNA and protein expression of apelin and APJ in porcine ovarian follicles of different sizes, and their immunolocalization and concentrations in follicular fluid and ovarian follicle, and 2) the direct effect of recombinant human apelin-13 on

• In conclusion our data highlight that variable anti oxidativ

  2024-01-25

  

  In conclusion, our data highlight that variable anti-oxidative p-Cresyl sulfate could be released through peptic hydrolysis of CMP fractions. Although casein hydrolysates produced a larger number of peptides (Table 1) with variable antioxidant capacities, all the peptides from whey hydrolysate exhi

• No starting dose adjustment is needed for

  2024-01-25

  

  No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad

• Modulating the ability of tumor cells to detoxify ROS

  2024-01-25

  

  Modulating the ability of tumor XL184 to detoxify ROS is a key mechanism by which cysteine metabolism affects tumor cell survival. One study observed hypermethylation of cysteine dioxygenase (CDO1) in 60% of tested breast cancer samples, leading to increased ROS detoxification and tumor cell surviv

• Accumulating evidence suggest that patients with advanced

  2024-01-25

  

  Accumulating evidence suggest that patients with advanced -positive NSCLC are at increased risk of VTE or coagulation disorders during the course of their disease, indicating that cancer genotype might play a role in the occurrence of cancer-related thromboembolism . Here we report the case of a pat

• BX-912 br Conclusions br Introduction During numerous

  2024-01-25

  

  Conclusions Introduction During numerous physiological processes, aldehydes are generated from a variety of endogenous and exogenous precursors including amino acids, carbohydrates, and lipids [1]. Most aldehydes are highly reactive and cytotoxic due to the strong electrophilic nature of the t

• Nitazoxanide sale br Acknowledgment br Introduction Vascular

  2024-01-25

  

  Acknowledgment Introduction Vascular smooth muscle cells (VSMC) exhibit the capacity to switch between a differentiated (contractile) and a dedifferentiated (synthetic) phenotype [1]. Synthetic VSMC express a lower amount of contractile proteins such as Smooth muscle 22α (sm22α) and α-Smooth m

• The extent to which GPCR oligomerization is a

  2024-01-24

  

  The extent to which GPCR oligomerization is a regulated process still remains unclear. Reported effects of ligands on both GPCR homo- and heteromers are highly variable and depend on GPCR subtypes and the specific ligand used. According to our data, chronic treatment of mice with both paroxetine or

• br Conclusion br Conflicts of

  2024-01-24

  

  Conclusion Conflicts of interest Introduction RNA interference is a specific post-transcriptional gene silencing mechanism within a cell via the transfection of microRNAs (miRNA), exogenous small interfering RNAs (siRNA) or small hairpin RNAs (shRNA) [1–3]. Transfection of shRNA can be done

• Imatinib is a well known anticancer drug used

  2024-01-24

  

  Imatinib is a well-known anticancer drug used in Chronic Myeloid Leukemia (CML) against the altered expression/activity of tyrosine kinase resulting from the fusion of BCR-ABL in leukemic blasts. It has been demonstrated that Imatinib can induce autophagy in BCR-ABL expressing WM-2474 australia (K5

• Imatinib is a well known anticancer drug used

  2024-01-24

  

  Imatinib is a well-known anticancer drug used in Chronic Myeloid Leukemia (CML) against the altered expression/activity of tyrosine kinase resulting from the fusion of BCR-ABL in leukemic blasts. It has been demonstrated that Imatinib can induce autophagy in BCR-ABL expressing Aripiprazole (K562 ce

• In clinical studies BA has been reported to

  2024-01-24

  

  In clinical studies, BA has been reported to promote dose-dependent LDL-C lowering effects of up to 30% as monotherapy, and up to an additional 24% when added in combination with stable statin therapy, or approximately 50% when combined with ezetimibe 109, 110, 111, 112. These effects were accompani

• We next sought to determine the kinase responsible for

  2024-01-24

  

  We next sought to determine the kinase responsible for IR-induced phosphorylation of 53BP1. Because the sites under investigation all lie in a consensus sequence for ATM, ATR and DNA-PK, that are all activated by IR, the involvement of each of these kinases was investigated. Preincubation of Icilin

16121 records 207/1075 page Previous Next First page 上5页 206207208209210 下5页 Last page